Is Asston Pharmaceu overvalued or undervalued?

As of 17 November 2025, the valuation grade for Asston Pharmaceu has moved from very expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 18.10, an EV to EBIT of 13.61, and a ROCE of 12.72%.
In comparison to its peers, Asston Pharmaceu's PE Ratio is significantly lower than that of Sun Pharma, which stands at 36.69, and Divi's Lab, which has a PE of 69.78, both of which are categorized as expensive. Conversely, it is on par with Aurobindo Pharma, which is also considered fair with a PE of 21.23. Notably, Asston Pharmaceu has outperformed the Sensex over the past week, returning 6.16% compared to the Sensex's 1.69%.